Network-based approaches for anticancer therapy (Review)

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1737-1744

  Seo, Hyunjeong ^a   Kim, Wanyeon ^a   Lee, Jihyung ^a   Youn, Buhyun ^a  

^a Pusan National University   (South Korea)

Author keywords

Chemotherapy; Complex network; Hub; Network flexibility; Radiotherapy

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; DENOSUMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EZN 2968; FIRTECAN PEGOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IDELALISIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; PROTEIN P53; RANIBIZUMAB; RNA; TRAMETINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CELL CYCLE; DNA REPAIR; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; KIDNEY CARCINOMA; MACROMOLECULE; METABOLITE; METASTASIS; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; TREATMENT RESPONSE;

HUMANS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84891923301     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2114     Document Type: Review

References (84)

1. Janes KA and Lauffenburger DA: A biological approach to computational models of proteomic networks. Curr Opin Chem Biol 10: 73-80, 2006.
2. Miller-Jensen K, Janes KA, Brugge JS and Lauffenburger DA: Common effector processing mediates cell-specific responses to stimuli. Nature 448: 604-608, 2007.
3. Jordan JD, Landau EM and Iyengar R: Signaling networks: the origins of cellular multitasking. Cell 103: 193-200, 2000.
4. Pawson T and Linding R: Network medicine. FEBS Lett 582: 1266-1270, 2008.
5. Vidal M, Cusick ME and Barabasi AL: Interactome networks and human disease. Cell 144: 986-998, 2011.
6. Vidal M: A unifying view of 21st century systems biology. FEBS Lett 583: 3891-3894, 2009.
7. Barabasi AL and Oltvai ZN: Network biology: understanding the cell's functional organization. Nature Rev Genet 5: 101-113, 2004.
8. Ideker T and Sharan R: Protein networks in disease. Genome Res 18: 644-652, 2008.
9. Rual JF, Venkatesan K, Hao T, et al: Towards a proteome-scale map of the human protein-protein interaction network. Nature 437: 1173-1178, 2005.
10. Stelzl U, Worm U, Lalowski M, et al: A human protein-protein interaction network: a resource for annotating the proteome. Cell 122: 957-968, 2005.
11. Jeong H, Tombor B, Albert R, Oltvai ZN and Barabasi AL: The large-scale organization of metabolic networks. Nature 407: 651-654, 2000.
12. Chang RL, Xie L, Bourne PE and Palsson BO: Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol 6: e1000938, 2010.
13. Schlitt T and Brazma A: Current approaches to gene regulatory network modelling. BMC Bioinformatics 8 (Suppl 6): S9, 2007.
14. Zhao Y, He S, Liu C, et al: MicroRNA regulation of messenger-like noncoding RNAs: a network of mutual microRNA control. Trends Genet 24: 323-327, 2008.
15. He X, He L and Hannon GJ: The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 67: 11099-11101, 2007.
16. Zhou Q, Chipperfield H, Melton DA and Wong WH: A gene regulatory network in mouse embryonic stem cells. Proc Natl Acad Sci USA 104: 16438-16443, 2007.
17. Barabasi AL and Albert R: Emergence of scaling in random networks. Science 286: 509-512, 1999.
18. Albert R, Jeong H and Barabasi AL: Error and attack tolerance of complex networks. Nature 406: 378-382, 2000.
19. Jeong H, Mason SP, Barabasi AL and Oltvai ZN: Lethality and centrality in protein networks. Nature 411: 41-42, 2001.
20. Park J and Newman ME: Statistical mechanics of networks. Phys Rev E Stat Nonlin Soft Matter Phys 70: 066117, 2004.
21. Albert R: Scale-free networks in cell biology. J Cell Sci 118: 4947-4957, 2005.
22. Fraser HB, Hirsh AE, Steinmetz LM, Scharfe C and Feldman MW: Evolutionary rate in the protein interaction network. Science 296: 750-752, 2002.
23. Kim PJ, Lee DY, Kim TY, et al: Metabolite essentiality elucidates robustness of Escherichia coli metabolism. Proc Natl Acad Sci USA 104: 13638-13642, 2007.
24. Zhang DY, Ye F, Gao L, et al: Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div 4: 20, 2009.
25. Ravasz E, Somera AL, Mongru DA, Oltvai ZN and Barabasi AL: Hierarchical organization of modularity in metabolic networks. Science 297: 1551-1555, 2002.
26. Han JD, Bertin N, Hao T, et al: Evidence for dynamically organized modularity in the yeast protein-protein interaction network. Nature 430: 88-93, 2004.
27. Barabasi AL, Gulbahce N and Loscalzo J: Network medicine: a network-based approach to human disease. Nature Rev Genet 12: 56-68, 2011.
28. Creixell P, Schoof EM, Erler JT and Linding R: Navigating cancer network attractors for tumor-specific therapy. Nat Biotechnol 30: 842-848, 2012.
29. Hwang S, Son SW, Kim SC, Kim YJ, Jeong H and Lee D: A protein interaction network associated with asthma. J Theor Biol 252: 722-731, 2008.
30. Jonsson PF and Bates PA: Global topological features of cancer proteins in the human interactome. Bioinformatics 22: 2291-2297, 2006.
31. Chuang HY, Lee E, Liu YT, Lee D and Ideker T: Network-based classification of breast cancer metastasis. Mol Syst Biol 3: 140, 2007.
32. Garcia M, Millat-Carus R, Bertucci F, Finetti P, Birnbaum D and Bidaut G: Interactome-transcriptome integration for predicting distant metastasis in breast cancer. Bioinformatics 28: 672-678, 2012.
33. Pache RA, Zanzoni A, Naval J, Mas JM and Aloy P: Towards a molecular characterisation of pathological pathways. FEBS Lett 582: 1259-1265, 2008.
34. Chand Y and Alam MA: Network biology approach for identifying key regulatory genes by expression based study of breast cancer. Bioinformation 8: 1132-1138, 2012.
35. Sonachalam M, Shen J, Huang H and Wu X: Systems biology approach to identify gene network signatures for colorectal cancer. Front Genet 3: 80, 2012.
36. Breitkreutz D, Hlatky L, Rietman E and Tuszynski JA: Molecular signaling network complexity is correlated with cancer patient survivability. Proc Natl Acad Sci USA 109: 9209-9212, 2012.
37. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
38. Goh KI, Cusick ME, Valle D, Childs B, Vidal M and Barabasi AL: The human disease network. Proc Natl Acad Sci USA 104: 8685-8690, 2007.
39. Han W and Lo HW: Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett 318: 124-134, 2012.
40. Laubenbacher R, Hower V, Jarrah A, et al: A systems biology view of cancer. Biochim Biophys Acta 1796: 129-139, 2009.
41. Sharma SV and Settleman J: ErbBs in lung cancer. Exp Cell Res 315: 557-571, 2009.
42. Chiang YJ, Difilippantonio MJ, Tessarollo L, Morse HC and Hodes RJ: Exon 1 disruption alters tissue-specific expression of mouse p53 and results in selective development of B cell lymphomas. PLoS One 7: e49305, 2012.
43. Erler JT and Linding R: Network medicine strikes a blow against breast cancer. Cell 149: 731-733, 2012.
44. Lee MJ, Ye AS, Gardino AK, et al: Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149: 780-794, 2012.
45. Pilpel Y, Sudarsanam P and Church GM: Identifying regulatory networks by combinatorial analysis of promoter elements. Nat Genet 29: 153-159, 2001.
46. Bhan A, Galas DJ and Dewey TG: A duplication growth model of gene expression networks. Bioinformatics 18: 1486-1493, 2002.
47. Pastor-Satorras R, Smith E and Sole RV: Evolving protein interaction networks through gene duplication. J Theor Biol 222: 199-210, 2003.
48. Gilmartin AG, Bleam MR, Groy A, et al: GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 17: 989-1000, 2011.
49. Duncan JS, Whittle MC, Nakamura K, et al : Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149: 307-321, 2012.
50. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
51. Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357: 39-51, 2007.
52. Crawford A and Nahta R: Targeting Bcl-2 in herceptin-resistant breast cancer cell lines. Curr Pharmacogenomics Person Med 9: 184-190, 2011.
53. Chan CH, Li CF, Yang WL, et al: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149: 1098-1111, 2012.
54. Figlin RA, Kaufmann I and Brechbiel J: Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer 133: 788-796, 2013.
55. Li L, Story M and Legerski RJ: Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys 49: 1157-1162, 2001.
56. Li YH, Wang X, Pan Y, Lee DH, Chowdhury D and Kimmelman AC: Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. PLoS One 7: e39588, 2012.
57. Sonoda E, Hochegger H, Saberi A, Taniguchi Y and Takeda S: Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair 5: 1021-1029, 2006.
58. Lhakhang TW and Chaudhry MA: Interactome of radiation-induced microRNA-predicted target genes. Comp Funct Genomics 2012: 569731, 2012.
59. Ma L, Nie L, Liu J, et al: An RNA-seq-based gene expression profiling of radiation-induced tumorigenic mammary epithelial cells. Genomics Proteomics Bioinformatics 10: 326-335, 2012.
60. Lee YS, Oh JH, Yoon S, et al: Differential gene expression profiles of radioresistant non-small-cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 77: 858-866, 2010.
61. Kalanxhi E and Dahle J: Genome-wide microarray analysis of human fibroblasts in response to gamma radiation and the radiation-induced bystander effect. Radiat Res 177: 35-43, 2012.
62. Kim KH, Yoo HY, Joo KM, et al: Time-course analysis of DNA damage response-related genes after in vitro radiation in H460 and H1229 lung cancer cell lines. Exp Mol Med 43: 419-426, 2011.
63. Xu QY, Gao Y, Liu Y, Yang WZ and Xu XY: Identification of differential gene expression profiles of radioresistant lung cancer cell line established by fractionated ionizing radiation in vitro. Chin Med J 121: 1830-1837, 2008.
64. Ding LH, Shingyoji M, Chen F, et al: Gene expression profiles of normal human fibroblasts after exposure to ionizing radiation: a comparative study of low and high doses. Radiat Res 164: 17-26, 2005.
65. Rashi-Elkeles S, Elkon R, Shavit S, et al: Transcriptional modulation induced by ionizing radiation: p53 remains a central player. Mol Oncol 5: 336-348, 2011.
66. Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121, 2001.
67. Somosy Z: Radiation response of cell organelles. Micron 31: 165-181, 2000.
68. Cao N, Li S, Wang Z, et al: NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res 171: 9-21, 2009.
69. Lee SY, Park HR, Cho NH, et al: Identifying genes related to radiation resistance in oral squamous cell carcinoma cell lines. Int J Oral Max Surg 42: 169-176, 2013.
70. Multhoff G and Radons J: Radiation, inflammation, and immune responses in cancer. Front Oncol 2: 58, 2012.
71. Brown JM and Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447, 2004.
72. Moeller BJ, Cao Y, Li CY and Dewhirst MW: Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer cell 5: 429-441, 2004.
73. Moeller BJ and Dewhirst MW: HIF-1 and tumour radiosensitivity. Br J Cancer 95: 1-5, 2006.
74. Kitano H: Biological robustness. Nature Rev Genet 5: 826-837, 2004.
75. Russell RB and Aloy P: Targeting and tinkering with interaction networks. Nat Chem Biol 4: 666-673, 2008.
76. Shao L, Wang L, Wei Z, et al: Dynamic network of transcription and pathway crosstalk to reveal molecular mechanism of MGd-treated human lung cancer cells. PLoS One 7: e31984, 2012.
77. Komurov K, Tseng JT, Muller M, et al: The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol 8: 596, 2012.
78. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538-5546, 2009.
79. Eschrich S, Zhang H, Zhao H, et al: Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys 75: 497-505, 2009.
80. Chiba M: Radiation-responsive transcriptome analysis in human lymphoid cells. Radiat Prot Dosimetry 152: 164-167, 2012.
81. Stiubea-Cohen R, David R, Neumann Y, et al: Effect of irradiation on cell transcriptome and proteome of rat submandibular salivary glands. PLoS One 7: e40636, 2012.
82. Russell JS, Brady K, Burgan WE, et al : Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63: 7377-7383, 2003.
83. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S and Haaf T: Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 62: 219-225, 2002.
84. Slupianek A, Hoser G, Majsterek I, et al: Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 22: 4189-4201,